Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Lenalidomide + Mosunetuzumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lenalidomide | Revlimid | IMiD-1 | Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov). | |
Mosunetuzumab | RG7828|BTCT4465A|RO7030816|BTCT-4465A | CD20 Antibody 14 | Mosunetuzumab (BTCT4465A) is a bispecific antibody targeting CD20 and CD3, which results in killing of CD20-positive tumor cells (PMID: 25972002, PMID: 29351372) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04246086 | Phase I | Tocilizumab Obinutuzumab Lenalidomide + Obinutuzumab + RO7082859 Lenalidomide + RO7082859 Lenalidomide + Mosunetuzumab | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len) or Glofitamab + Len With or Without Obinutuzumab; and Evaluating the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With R/R Follicular Lymphoma | Recruiting | USA | FRA | ESP | 2 |
NCT04792502 | Phase II | Lenalidomide + Mosunetuzumab | Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | Not yet recruiting | USA | 0 |